Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels

Anticancer Research

Volumn 28, Issue 1 B, 2008, Pages 395-399

  Licastro, Federico ^a   Bertaccini, Alessandro ^b   Porcellini, Elisa ^a   Chiappelli, Martina ^a   Pernetti, Remigio ^b   Sanguedolce, Francesco ^b   Marchiori, Debora ^b   Martorana, Giuseppe ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ACT; Inflammation; Promoter polymorphism; Prostate cancer; PSA levels

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DNA EXTRACTION; GENE FREQUENCY; GENETIC MARKER; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 40549087919     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. Cancer J Clin 55: 10-30, 2005. Erratum in: Cancer J Clin 55: 259.
2. Lichtenstein P, Holm NV, Verkasalo PK, Lichtenstein, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85, 2000.
3. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
4. Mahmud S, Franco E and Aprikian A: Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 90: 93-99, 2004.
5. Sun J, Turner A, Xu J, Gronberg H and Isaacs W: Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 25: 250-259, 2007.
6. Sutcliffe S and Platz EA: Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol 25: 242-249, 2007.
7. McCarron SL, Edwards S, Evans PR, McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA and Howell WM: Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62: 3369-3372, 2002.
8. Latif Z, McMillan DC, Wallace AM, Sattar N, Mir K, Jones G and Underwood MA: The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate- specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 89: 396-399, 2002.
9. Polascik TJ, Oesterling JE and Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306, 1999.
10. Bjork T, Bjartell A, Abrahamsson PA Hulkko S, Di Sant'Agnese A and Lilja H: Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 43: 427-434, 1994.
11. Kobayashi T, Kamoto T, Isogawa Y, Kinoshita H, Terai A, Habuchi T and Ogawa O: Ratio of prostate specific antigen minor molecular forms-to-total prostate specific antigen is constant regardless of the pathological condition of the prostate. J Urol 169: 121-124, 2003.
12. Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D and Loening SA: A multicenter clinical trial on the use of alphal-antichymotrypsinprostate- specific antigen in prostate cancer diagnosis. Prostate 47: 77-84, 2001.
13. Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP and Cheli CD: Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol 170: 1787-1791, 2003.
14. Bjork T, Piironen T, Pettersson K, Lovgren T, Stenman UH, Oesterling JE, Abrahamsson PA and Lilja H: Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 48: 882-888, 1996.
15. Ravaglia G, Forti P, Maioli F, Scali RC, Arnone G, Talerico T, Pantieri T, Nativio V, Mantovani V and Bianchin M: Common polymorphisms in methylentetrahydropholate reductase (MTHFR): relationship with plasma homocysteine concentrations and cognitive status in elderly northern Italian subjects. In proceeding Arch Gerontol Geriat Suppl 9: 339-348, 2004.
16. Licastro F, Chiappelli M, Grimaldi LM, Morgan K, Kalsheker N, Calabrese E, Ritchie A, Porcellini E, Salani G, Franceschi M and Canal N: A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease. Neurobiol Aging 26: 449-453, 2005.
17. Morgan K, Licastro F, Tilley L, Ritchie A, Morgan L, Pedrini S and Kalsheker N: Polymorphism in the alpha(1)-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations. Hum Genet 109: 303-310, 2004.